argenx SE American Depositary Shares - ARGX STOCK NEWS

argenx SE has initiated a global offering of $500 million in ordinary shares, potentially represented by American Depository Shares (ADSs). This offering includes a public offering in the U.S. and a private placement in Europe. The offering aims to close on a simultaneous basis. Additionally, underwriters may purchase up to 15% more shares. Notably, Baillie Gifford has expressed interest in acquiring up to $170 million of shares. The offering is overseen by J.P. Morgan, Morgan Stanley, Cowen, and SVB Leerink, with securities offered under a previously filed SEC registration statement.

argenx SE (Euronext & Nasdaq: ARGX) announced positive topline results from the Phase 3 ADAPT-SC study, showing that subcutaneous efgartigimod achieved noninferior total IgG reduction in generalized myasthenia gravis patients compared to intravenous administration. The study met its primary endpoint with a 66.4% IgG reduction at day 29, versus 62.2% for VYVGART. The company plans to submit a Biologics License Application (BLA) to the FDA by the end of 2022, aiming to enhance treatment options for patients and address the need for individualized care.

argenx reported a transformational year in 2021, highlighted by the FDA approval and U.S. launch of VYVGART, the first FcRn blocker for generalized myasthenia gravis. Full-year revenue soared to $497.3 million, a substantial increase from $41.2 million in 2020, primarily due to collaboration agreements. However, operating losses decreased to $348.7 million from $477.6 million the previous year. The company anticipates utilizing up to half of its cash reserves in 2022 to support the global launch of VYVGART and expand its pipeline with new indications.

February 28, 2022 – argenx (Euronext & Nasdaq: ARGX) announced its participation in the 42nd Annual Cowen Health Care Conference on March 7, 2022, at 2:10 p.m. E.T. Management will engage in a fireside chat during the event. Interested parties can access a live webcast via the Investors section of the argenx website, with a replay available for 90 days after the presentation. argenx specializes in creating innovative therapies for severe autoimmune diseases.

argenx (Euronext & Nasdaq: ARGX) announced a conference call on March 3, 2022, at 2:30 pm CET (8:30 am ET) to discuss its full year 2021 financial results and provide a fourth quarter business update. The call will be accessible via the Investors section on the company's website. A replay will be available for a year after the call. argenx focuses on developing innovative treatments for severe autoimmune diseases and has commercialized the first approved neonatal Fc receptor blocker in the U.S. and Japan.

February 10, 2022 – argenx (Euronext & Nasdaq: ARGX), a global immunology company focused on severe autoimmune diseases, will participate in a fireside chat at the 11^th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 10:40 a.m. ET. A live webcast can be accessed on their Investors section of the argenx website, with a replay available for 90 days. argenx is known for developing the first approved neonatal Fc receptor blocker in the U.S. and Japan and is advancing various treatments for autoimmune diseases.

VYVGART™ (efgartigimod alfa), the first and only FcRn blocker, has received approval from Japan's Ministry of Health, Labour and Welfare for treating adults with generalized myasthenia gravis (gMG) unresponsive to standard therapies. This marks the second regulatory approval following its U.S. authorization on December 17, 2021. The approval supports argenx's global strategy to enhance access to this innovative treatment. VYVGART demonstrated significant efficacy in the Phase 3 ADAPT trial, showcasing superior response rates compared to placebo, reinforcing its potential in managing gMG.

argenx has announced the global commercial launch of VYVGART™ for the treatment of generalized myasthenia gravis. The company expects to report data from five registrational trials of efgartigimod by Q1 2023 and plans to initiate trials in four new indications, including lupus nephritis and Sjogren’s syndrome, in 2022. With approximately $2.3 billion in cash as of December 31, 2021, argenx anticipates a busy 2022, focusing on expanding its efgartigimod portfolio and maintaining its leadership in FcRn blockade.

argenx (Euronext & Nasdaq: ARGX), a global immunology company, announced that CEO Tim Van Hauwermeiren will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 7:30 a.m. ET. A live webcast will be available in the Investors section of the argenx website. The company is focused on severe autoimmune diseases and is commercializing VYVGART (efgartigimod alfa-fcab), the first FDA-approved neonatal Fc receptor blocker for generalized myasthenia gravis in adult patients. For more details, visit argenx.com.